Dr. Linda Spencer, MD

Education:

College: Northwestern University, Evanston, Illinois, BSc 1981 

Medical School:  University of Illinois College of Medicine, Chicago, Illinois, M.D. 1985

Honors in Internal Medicine, Pediatrics, Ob/Gyn, Dermatology, Emergency Medicine, Neurology, Ophthalmology, Psychiatry, Family PracticeInternship: Univ. of Illinois, Chicago, Illinois, Internal Medicine, 1985 – 1986

Residency: Univ. of Louisville, Louisville, KY, Dermatology, 1986 – 1989

Chief Resident, Division of Dermatology, 1988 – 1989

Board Certification:  American Board of Dermatology (lifetime), 1989

Continuing Medical Education: Certification from American Board of Dermatology. Current through July 2011

Professional memberships:

• American Academy of Dermatology (Fellow)
• Dermatology Foundation, Leaders Society
• Indiana State Medical Association
• Indiana Dermatology Society

Publications:

1. “Porokeratosis.” In eMedicine Dermatology, an online dermatology textbook.
2. Callen JP, Spencer LV, Burrus JB, et al: Azathioprine: An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocuytoclastic vasculitis. Arch Dermatol, Vol 127; 515-522, April 1991.
3. Purcell KG, Spencer LV, Simpson PM et al: HLA antigens in lichen sclerosus et atrophicus. Arch Dermatol. Vol 126; 1043-1045, August 1990.
4. Spencer LV, Callen JP: Primary cutaneous B-cell lymphoma presenting as hypertrophic stasis dermatitis.  Clin Dermatol, 1989.
5. Roth DE, Spencer LV, Ahrens EM: Cutaneous reactions to drugs used for rheumatologic disorders. Clin Dermatol.
6. Spencer LV, Callen JP: Cutaneous manifestations of bacterial infections. Dermatologic Clinics 7: 579-589, 1989.
7. Spencer LV, Callen JP: Hair loss in systemic disease. Dermatology Clinics 5: 565-570, 1987.
8. Spencer LV, Fowler JF: “Thin mint” cookie dermatitis. Contact Dermatitis, Vol 18: 186-186, March 1988.
9. Fabre VC, Sewell C, Spencer LV, et al: A unique presentation of syringocystadenoma papilliferum. Southern Med Assoc, November 1989.
   

Clinical Trials and Studies:

1. Observational Post-Marketing Safety Surveillance Registry of Enbrel (etanercept) for Treatment of Psoriasis, an Observational Safety Study of Enbrel for Treatment of Psoriasis, Amgen Protocol 20040210, 2006 – present.
2. Experience Diagnosing, Understanding Care, and Treatment with Enbrel in Psoriatic Arthritis (EDUCATE in PsA) Amgen Protocol 20030106, 2003 – 2004.
3. A Phase IIIb, Open-Label, Multicenter Study To Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab In Adults with Moderate To Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies Or Have Recently Transitioned From Systemic Therapies, Genentech Protocol #ACD2782g, 2004.
4. Assessment and Tracking of Long-term Alefacept (LFA-31gG1 Fusion Protein) Safety (“ATLAS”) Biogen Idec Study C-736 (2003 – present).
5. Soriatane liver toxicity study, Roche, 1987 – 1988.

Community Activities:

1. First Christian Church, Crawfordsville, Indiana
2. Trustee, Christian Theological Seminary, 2008 - present
3. USA Swimming Official (certification through 2012)
4. Art League Group K
5. Past board member, Family Crisis Shelter, Montgomery United Foundation For You, Montgomery County’s Junior Miss, American Cancer Society